SCHEMBL6930158

SCHEMBL6930158

Fc1ccc2oc(CBr)nc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 1/20 0.43
PIK3CB P42338 1/20 0.43
MPO P05164 1/20 0.42
GRK6 P43250 1/20 0.41
ELANE P08246 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
DAGLA Q9Y4D2 1/20 0.39
MAPT P10636 3/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
KDM4E B2RXH2 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
HSD17B10 Q99714 1/20 0.39
GABRP O00591 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5794092 0.86 MAPT (0.46) PIK3CDPIK3CBELANEDAGLAMAPT
SCHEMBL11325989 0.85 PIK3CD (0.51) PIK3CDPIK3CBMPOGRK6MEN1
SCHEMBL13565572 0.82 GAA (0.55) PIK3CDPIK3CBMPOGRK6MEN1
SCHEMBL22042886 0.82 MPO (0.46) PIK3CDPIK3CBMPOGRK6MEN1
SCHEMBL29491254 0.82 PIK3CD (0.43) PIK3CDPIK3CBMPOGRK6MEN1
SCHEMBL24338807 0.82 PIK3CD (0.43) PIK3CDPIK3CBMPOGRK6MEN1
SCHEMBL30612621 0.82 MPO (0.46) PIK3CDPIK3CBMPOGRK6MEN1
SCHEMBL22042970 0.82 PIK3CD (0.43) PIK3CDPIK3CBMPOGRK6MEN1
SCHEMBL2794701 0.82 PIK3CD (0.43) PIK3CDPIK3CBMPOGRK6MEN1
SCHEMBL9207558 0.80 XDH (0.43) GRK6ELANEMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011012622-A1 BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF GLYTL MEDIATED DISORDERS GLAXO GROUP LIMITED (GB) 2011-02-03 WO disclosed